Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Persistent Allergic Asthma
NCT00870584Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2009
- Primary completion
- Mar 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in allergic asthma comparing Omalizumab with Placebo (2 arms). Primary endpoint: Asthma Control Test at 24 weeks. Started Mar 2009; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00870584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00870584.